Ervi Salwati1, Gabriela Minigo2,3, Tonia Woodberry2, Kim A Piera2, Harini D de Silva4, Enny Kenangalem5, Emiliana Tjitra1, Ross L Coppel4, Ric N Price2,6,7, Nicholas M Anstey2,7, Magdalena Plebanski3. 1. National Institute of Health Research and Development (NIHRD), Ministry of Health, Jakarta, Indonesia. 2. Global Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia. 3. Department of Immunology, Monash University, Victoria, Australia. 4. Department of Microbiology, Monash University, Victoria, Australia. 5. Menzies-NIHRD Collaborative Research Program and District Health Authority, Timika, Papua, Indonesia. 6. Centre for Vaccinology and Tropical Medicine, Nuffield Department of Clinical Medicine, Churchill Hospital, Oxford. 7. Division of Medicine, Royal Darwin Hospital, Darwin, Australia.
Abstract
BACKGROUND: Plasmodium falciparum and Plasmodium vivax are co-endemic in the Asia-Pacific region. Their capacity to induce and sustain diverse T-cell responses underpins protective immunity. We compared T-cell responses to the largely conserved merozoite surface protein-5 (PfMSP5) during acute and convalescent falciparum and vivax malaria. METHODS: Lymphoproliferation and IFN--γ secretion to PfMSP5 and purified protein derivate were quantified in adults with falciparum (n=34), and vivax malaria (n=12) or asymptomatic residents (n=10) of Papua, Indonesia. Responses were reassessed 7-28 days following treatment. RESULTS: The frequency of IFN-γ responders to PfMSP5 was similar in acute falciparum (63%) or vivax (67%) malaria. However, significantly more IFN-γ-secreting cells were detectable during vivax compared with falciparum infection. Purified protein derivative responses showed a similarly enhanced pattern. While rapidly lost in vivax patients, PfMSP5-specific responses in falciparum malaria remained to day 28. By contrast, frequency and magnitude of lymphoproliferation to PfMSP5 were similar for falciparum and vivax infections. CONCLUSION: Cellular PfMSP5-specific responses are most frequent during either acute falciparum or vivax malaria, indicating functional T-cell responses to conserved antigens. Both effector and central memory T-cell functions are increased. Greater IFN-γ responses in acute P. vivax, suggest enhancement of pre-existing effector T-cells during acute vivax infection.
BACKGROUND:Plasmodium falciparum and Plasmodium vivax are co-endemic in the Asia-Pacific region. Their capacity to induce and sustain diverse T-cell responses underpins protective immunity. We compared T-cell responses to the largely conserved merozoite surface protein-5 (PfMSP5) during acute and convalescent falciparum and vivax malaria. METHODS: Lymphoproliferation and IFN--γ secretion to PfMSP5 and purified protein derivate were quantified in adults with falciparum (n=34), and vivax malaria (n=12) or asymptomatic residents (n=10) of Papua, Indonesia. Responses were reassessed 7-28 days following treatment. RESULTS: The frequency of IFN-γ responders to PfMSP5 was similar in acute falciparum (63%) or vivax (67%) malaria. However, significantly more IFN-γ-secreting cells were detectable during vivax compared with falciparum infection. Purified protein derivative responses showed a similarly enhanced pattern. While rapidly lost in vivax patients, PfMSP5-specific responses in falciparum malaria remained to day 28. By contrast, frequency and magnitude of lymphoproliferation to PfMSP5 were similar for falciparum and vivax infections. CONCLUSION: Cellular PfMSP5-specific responses are most frequent during either acute falciparum or vivax malaria, indicating functional T-cell responses to conserved antigens. Both effector and central memory T-cell functions are increased. Greater IFN-γ responses in acute P. vivax, suggest enhancement of pre-existing effector T-cells during acute vivax infection.
Authors: Ann M Moormann; Kiprotich Chelimo; Peter O Sumba; Daniel J Tisch; Rosemary Rochford; James W Kazura Journal: J Infect Dis Date: 2007-02-06 Impact factor: 5.226
Authors: Ric N Price; Emiliana Tjitra; Carlos A Guerra; Shunmay Yeung; Nicholas J White; Nicholas M Anstey Journal: Am J Trop Med Hyg Date: 2007-12 Impact factor: 2.345
Authors: Tonia Woodberry; Gabriela Minigo; Kim A Piera; Jennifer C Hanley; Harini D de Silva; Ervi Salwati; Enny Kenangalem; Emiliana Tjitra; Ross L Coppel; Ric N Price; Nicholas M Anstey; Magdalena Plebanski Journal: J Infect Dis Date: 2008-07-01 Impact factor: 5.226
Authors: Philip Bejon; Jedidah Mwacharo; Oscar Kai; Stephen Todryk; Sheila Keating; Brett Lowe; Trudie Lang; Tabitha W Mwangi; Sarah C Gilbert; Norbert Peshu; Kevin Marsh; Adrian V S Hill Journal: J Immunol Date: 2007-09-15 Impact factor: 5.422
Authors: Ramou Njie; Andrew I Bell; Hui Jia; Debbie Croom-Carter; Sridhar Chaganti; Andrew D Hislop; Hilton Whittle; Alan B Rickinson Journal: J Infect Dis Date: 2009-01-01 Impact factor: 5.226
Authors: Muhammad Karyana; Lenny Burdarm; Shunmay Yeung; Enny Kenangalem; Noah Wariker; Rilia Maristela; Ketut Gde Umana; Ram Vemuri; Maurits J Okoseray; Pasi M Penttinen; Peter Ebsworth; Paulus Sugiarto; Nicholas M Anstey; Emiliana Tjitra; Richard N Price Journal: Malar J Date: 2008-08-02 Impact factor: 2.979
Authors: Gabriela Minigo; Tonia Woodberry; Kim A Piera; Ervi Salwati; Emiliana Tjitra; Enny Kenangalem; Ric N Price; Christian R Engwerda; Nicholas M Anstey; Magdalena Plebanski Journal: PLoS Pathog Date: 2009-04-24 Impact factor: 6.823
Authors: Kirsty L Wilson; Dodie Pouniotis; Jennifer Hanley; Sue D Xiang; Charles Ma; Ross L Coppel; Magdalena Plebanski Journal: Front Immunol Date: 2019-03-15 Impact factor: 7.561